DOI 10.1016/j.bjorl.2026.101856
Secretoneurin as a novel predictor of metabolic syndrome in patients with obstructive sleep apnea syndrome.
Аннотация
OBJECTIVE
This study aimed to evaluate whether Secretoneurin (SN) was elevated in Metabolic Syndrome (MetS) and could serve as a potential predictive biomarker in the development of MetS in patients with Obstructive Sleep Apnea Syndrome (OSAS).
METHODS
This cross-sectional study included 86 consecutive participants. Following anthropometric measurements, blood tests, polysomnography, and blood pressure assessments, the participants were categorized into three groups: the MetS(+) OSAS group, the MetS(-) OSAS group, and the control group without MetS or OSAS. Serum SN levels were measured using the enzyme-linked immunosorbent assay method.
RESULTS
The SN levels (pmol/L) of the MetS(+) OSAS group were statistically higher than those of the MetS(-) OSAS group and the control group (p < 0.033). A positive and statistically significant correlation was observed between SN levels (pmoL/L) and serum triglyceride levels (mg/dL) (r = 0.244, p = 0.024 < 0.05).
CONCLUSIONS
This study indicates that SN may have predictive value in the development of MetS in patients with OSAS.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.